13,400 glyphosate lawsuits against BayerBayer said in its results call on Thursday that lawsuits from approximately 13,400 plaintiffs have been served on Bayer’s subsidiary Monsanto in the U.S. over glyphosate-based weed killers, Sueddeutsche Zeitung says on Friday (p19). (APMHE 62783)
More cannabis drugs should be approved - BfArMGerman drug regulator BfArM would like to see more standardised cannabis drugs on the German market instead of the use of plant parts for medical purposes, which should only be a "temporary arrangement", BfArM's head Karl Broich told Handelsblatt on Tuesday (p21).
Novartis and Amgen in legal dispute over AimovigNovartis is suing Amgen over its attempt to end their collaboration on migraine treatment Aimovig (erenumab) (APMHE 62571), FAZ reported on Thursday (p18).
AI predicted Biogen/Eisai's trial failureGerman-Indian company Innoplexus has developed artificial intelligence that was able to predict the failure of Biogen/Eisai's Phase III failure of drug candidate aducanumab in Alzheimer’s (APMHE 62348) months before, FAZ reported on Thursday (p32).
Merck KGaA forecasts pharma growthMerck KGaA can expect its pharma business to grow this year with its new multiple sclerosis drug Mavenclad (cladribine) and immune-oncology drug Bavencio (avelumab) showing potential for €500 million in sales (APMHE 62161), Handelsblatt reported on Thursday (p18-21).
TRY APM HEALTH EUROPE AND GET ACCESS TO THE FULL CONTENT
Interviews with KOLs/senior executives amongst the Regulators, Payers, Health, Medical & Pharmaceutical organisations
Events coverage with a unique focus on Market Access & sustainability of healthcare systems
6 European bureaus : Berlin, Brussels, London, Madrid, Milan & Paris
Ask for a Free trial and get access to the latest stories
- Health Care
- Market Access
- HTA – policies & practices
- European medicine regulations
- Drug safety issues
- Pricing & Reimbursement
- International medicines agencies
If you are a Payer, Pharmaceutical or Consulting professional our premium data will keep you informed on the regulatory, pricing, market access and cost-effectiveness issues that impact all stakeholders.
an initial 10 day temporary access of APM Health Europe.